Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: The oligometastatic paradigm postulates that patients with a limited number of metastases can be treated with ablative local therapy to each site of disease with curative intent. Stereotactic ablative radiotherapy (SABR) is a radiation technique that has become widely used in this setting. However, prospective data are limited and are mainly from single institutional studies. OBJECTIVE: To conduct a meta-analysis to characterize the safety and clinical benefit of SABR in oligometastatic cancer. DATA SOURCES: A comprehensive search was conducted in PubMed/MEDLINE, Embase, Cochrane Database of Systematic Reviews, and Cumulative Index to Nursing and Allied Health Literature on December 23, 2019, that included prospective clinical trials and review articles that were published within the past 15 years. STUDY SELECTION: Inclusion criteria were single-arm or multiarm prospective trials including patients with oligometastatic cancer (ie, ≤5 sites of extracranial disease), and SABR was administered in less than or equal to 8 fractions with greater than or equal to 5 Gy/fraction. DATA EXTRACTION AND SYNTHESIS: The Population, Intervention, Control, Outcomes and Study Design; Preferred Reporting Items for Systematic Reviews and Meta-analyses; and Meta-analysis of Observational Studies in Epidemiology methods were used to identify eligible studies. Study eligibility and data extraction were reviewed by 3 authors independently. Random-effects meta-analyses using the Knapp-Hartung correction, arcsine transformation, and restricted maximum likelihood method were conducted. MAIN OUTCOMES AND MEASURES: Safety (acute and late grade 3-5 toxic effects) and clinical benefit (1-year local control, 1-year overall survival, and 1-year progression-free survival). RESULTS: Twenty-one studies comprising 943 patients and 1290 oligometastases were included. Median age was 63.8 years (interquartile range, 59.6-66.1 years) and median follow-up was 16.9 months (interquartile range, 13.7-24.5 months). The most common primary sites were prostate (22.9%), colorectal (16.6%), breast (13.1%), and lung (12.8%). The estimate for acute grade 3 to 5 toxic effect rates under the random-effects models was 1.2% (95% CI, 0%-3.8%; I2 = 50%; 95% CI, 3%-74%; and τ = 0.20%; 95% CI, 0.00%-1.43%), and the estimate for late grade 3 to 5 toxic effects was 1.7% (95% CI, 0.2%-4.6%; I2 = 54%; 95% CI, 11%-76%; and τ = 0.25%; 0.01%-1.00%). The random-effects estimate for 1-year local control was 94.7% (95% CI, 88.6%-98.6%; I2 = 90%; 95% CI, 86%-94%; and τ = 0.81%; 95% CI, 0.36%-2.38%]). The estimate for 1-year overall survival was 85.4% (95% CI, 77.1%-92.0%; I2 = 82%; 95% CI, 71%-88%; and τ = 0.72%; 95% CI, 0.30%-2.09%) and 51.4% (95% CI, 42.7%-60.1%; I2 = 58%; 95% CI, 17%-78%; and τ = 0.20%; 95% CI, 0.02%-1.21%) for 1-year progression-free survival. CONCLUSIONS AND RELEVANCE: In this meta-analysis, SABR appears to be relatively safe in patients with oligometastatic cancer with clinically acceptable rates of acute and late grade 3 to 5 toxic effects less than 13% and with clinically acceptable rates of 1-year local control overall survival, and progression-free survival. These findings are hypothesis generating and require validation by ongoing and planned prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
The well-built clinical question: A key to evidence-based decisions
(1995) · ACP Journal Club · doi:10.7326/acpjc-1995-123-3-a12 · Cited by 2,931
Transformations Related to the Angular and the Square Root
Freeman, M. F., & Tukey, J. W. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729756 · Cited by 2,628
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Comparison of two methods to detect publication bias in meta-analysis.
Peters, J. L. (2006) · JAMA · doi:10.1001/jama.295.6.676 · Cited by 2,278
Plea for routinely presenting prediction intervals in meta-analysis.
IntHout, J., Ioannidis, J. P. A., Rovers, M. M., & Goeman, J. J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010247 · Cited by 2,264
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Self-citationPalma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00818 · Cited by 1,300
Undue reliance on I 2 in assessing heterogeneity may mislead
Rücker, G., Schwarzer, G., Carpenter, J. R., & Schumacher, M. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-79 · Cited by 1,287
Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0147 · Cited by 1,159
Guckenberger, M., Lievens, Y., Bouma, A. B., Collette, L., Dekker, A., deSouza, N. M., Dingemans, A.-M. C., Fournier, B., Hurkmans, C., Lecouvet, F. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30718-1 · Cited by 1,111
Self-citationMulti-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., Pugh, T. J., Kane, M., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082
A comparison of heterogeneity variance estimators in simulated random‐effects meta‐analyses
Langan, D., Higgins, J. P. T., Jackson, D., Bowden, J., Veroniki, A. A., Kontopantelis, E., Viechtbauer, W., & Simmonds, M. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1316 · Cited by 1,074
Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Evaluation of PICO as a knowledge representation for clinical questions.
Huang, X., Lin, J., & Demner‐Fushman, D. (2006) · Europe PMC (PubMed Central) · Cited by 898
The Interpretation of Random-Effects Meta-Analysis in Decision Models
Ades, A. E., Lu, G., & Higgins, J. P. T. (2005) · Medical Decision Making · doi:10.1177/0272989x05282643 · Cited by 859
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J. I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.057 · Cited by 829
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6329 · Cited by 805
Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., Kindts, I., Méndez Romero, A., Nevens, D., Palma, D., Park, C., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.04.003 · Cited by 672
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Méndez Romero, A., Wunderink, W., Hussain, S. M., De Pooter, J. A., Heijmen, B. J. M., Nowak, P. C. J. M., Nuyttens, J. J., Brandwijk, R. P., Verhoef, C., Ijzermans, J. N. M., et al. (2006) · Acta Oncologica · doi:10.1080/02841860600897934 · Cited by 498
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0062 · Cited by 463
Fleiss, J. L., & Gross, A. J. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90261-7 · Cited by 404
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy
Barney, J. D., & Churchill, E. J. (1939) · Journal of Urology · doi:10.1016/s0022-5347(17)71516-9 · Cited by 359
Siva, S., Bressel, M., Murphy, D. G., Shaw, M., Chander, S., Violet, J., Tai, K. H., Udovicich, C., Lim, A., Selbie, L., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.004 · Cited by 322
Self-citationSalama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., Villaflor, V. M., Stadler, W. M., Hoffman, P. C., Cohen, E. E. W., et al. (2012) · Cancer · doi:10.1002/cncr.26611 · Cited by 320
Palma, D. A., Haasbeek, C. J. A., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., Olson, R., Liu, M., Panarotto, J., Griffioen, G., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-305 · Cited by 302
Wang, X. S., Rhines, L. D., Shiu, A. S., Yang, J. N., Selek, U., Gning, I., Liu, P., Allen, P. K., Azeem, S. S., Brown, P. D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70384-9 · Cited by 300
Iyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7412 · Cited by 286
Common Terminology Criteria for Adverse Events, version 5.0
(2025) · Oxford Handbook of Oncology · doi:10.1093/med/9780198847168.005.0001 · Cited by 265
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
Self-citationPalma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5977-6 · Cited by 260
Pitroda, S. P., Khodarev, N. N., Huang, L., Uppal, A., Wightman, S. C., Ganai, S., Joseph, N., Pitt, J., Brown, M., Forde, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04278-6 · Cited by 254
Garg, A. K., Shiu, A. S., Yang, J., Wang, X., Allen, P., Brown, B. W., Grossman, P., Frija, E. K., McAleer, M. F., Azeem, S., et al. (2012) · Cancer · doi:10.1002/cncr.27530 · Cited by 210
Lussier, Y. A., Khodarev, N. N., Regan, K., Corbin, K., Li, H., Ganai, S., Khan, S. A., Gnerlich, J., Darga, T. E., Fan, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050141 · Cited by 201
Scorsetti, M., Comito, T., Tozzi, A., Navarria, P., Fogliata, A., Clerici, E., Mancosu, P., Reggiori, G., Rimassa, L., Torzilli, G., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1833-x · Cited by 174
Zaorsky, N. G., Lehrer, E. J., Kothari, G., Louie, A. V., & Siva, S. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.05.007 · Cited by 160
Self-citationThe rise in metastasectomy across cancer types over the past decade
Bartlett, E. K., Simmons, K. D., Wachtel, H., Roses, R. E., Fraker, D. L., Kelz, R. R., & Karakousis, G. C. (2014) · Cancer · doi:10.1002/cncr.29134 · Cited by 153
Random-Effects Meta-analysis: Summarizing Evidence With Caveats
Serghiou, S., & Goodman, S. N. (2019) · JAMA · doi:10.1001/jama.2018.19684 · Cited by 151
Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases
Lewis, S. L., Porceddu, S. V., Nakamura, N., Palma, D. A., Lo, S. S.-M., Hoskin, P., Moghanaki, D. M., Chmura, S. J., & Salama, J. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000169 · Cited by 151
Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
Milano, M. T., Zhang, H., Metcalfe, S. K., Muhs, A. G., & Okunieff, P. G. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0157-4 · Cited by 150
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
Ahmed, K. A., Barney, B. M., Davis, B. J., Park, S. S., Kwon, E. D., & Olivier, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2012.00215 · Cited by 141
Fode, M. M., & Høyer, M. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.12.003 · Cited by 119
Information at the Point of Care: Answering Clinical Questions
Ebell, M. H. (1999) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.12.3.225 · Cited by 110
Sutera, P. A., Clump, D. A., Kalash, R., D'Ambrosio, D. J., Mihai, A., Wang, H., Petro, D. P., Burton, S. A., & Heron, D. E. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.08.027 · Cited by 85
David, S., Tan, J., Savas, P. S., Bressel, M., Kelly, D., Foroudi, F., Loi, S., & Siva, S. (2019) · The Breast · doi:10.1016/j.breast.2019.10.016 · Cited by 82
Self-citationStereotactic Body Radiation Therapy for Oligometastases to the Lung: A Phase 2 Study
Nuyttens, J. J. M. E., van Zyp, N. V. D. V., Verhoef, C. K., Maat, A. P. W. M., van Klaveren, R. J., van der Holt, B., Aerts, J. G. J. V., & Hoogeman, M. S. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.10.021 · Cited by 73
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases
Lehrer, E. J., McGee, H. M., Peterson, J., Vallow, L. A., Ruiz-Garcia, H. J., Zaorsky, N. G., Sharma, S., & Trifiletti, D. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103054 · Cited by 64
Self-citationPembroke, C., Fortin, B., & Kopek, N. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.04.022 · Cited by 39
Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer
Pasqualetti, F., Panichi, M., Sainato, A., Baldaccini, D., Cocuzza, P., Gonnelli, A., MONTRONE, S., Molinari, A., Barbiero, S., Bruschi, A., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12572 · Cited by 16
Cited by
Radiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
Bhat, V., Pellizzari, S., Allan, A. L., Wong, E., Lock, M., Brackstone, M., Lohmann, A. E., Cescon, D. W., & Parsyan, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103566 · Cited by 31
Zhu, Z., Wu, M., Sun, J., Huangfu, Z., Yin, L., Yong, W., Sun, J., Wang, G., Meng, F., & Zhong, Z. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1995080 · Cited by 17
“Radiotherapy (RT) is one of the most widely used and effective treatments for malignant solid tumors in clinical settings (Citrin, 2017; Pallares & Abergel, 2020; Lehrer et al., 2021).”
Background
Metadata
- Authors
- Lehrer, E. J., Singh, R., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L., & Zaorsky, N. G.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 92
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3107300149
- Cited by
- 196
- References
- 60
- FWCI
- 22.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.